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Objective:A recent randomized trial suggested nitinol self-expanding stents (SES) were associated with reduced restenosis
rates compared with simple percutaneous transluminal angioplasty (PTA). We evaluated our results with superficial
femoral artery (SFA) SES to determine whether TransAtlantic InterSociety Consensus (TASC) classification, indication
for intervention, patient risk factors, or Society of Vascular Surgery (SVS) runoff score correlated with patency and
clinical outcome, and to evaluate if bare nitinol stents or expanded polytetrafluoroethylene (ePTFE) covered stent
placement adversely impacts the tibial artery runoff.
Methods:A total of 109 consecutive SFA stenting procedures (95 patients) at two university-affiliated hospitals from 2003
to 2006 were identified. Medical records, angiographic, and noninvasive studies were reviewed in detail. Patient
demographics and risk factors were recorded. Procedural angiograms were classified according to TASC Criteria (I-2000
and II-2007 versions) and SVS runoff scores were determined in every patient; primary, primary-assisted, secondary
patency, and limb salvage rates were calculated. Cox proportional hazard model was used to determine if indication,
TASC classification, runoff score, and comorbidities affected outcome.
Results: Seventy-one patients (65%) underwent SES for claudication and 38 patients (35%) for critical limb ischemia
(CLI). Average treatment length was 15.7 cm, average runoff score was 4.6. Overall 36-month primary, primary-assisted,
and secondary rates were 52%, 64%, and 59%, respectively. Limb salvage was 75% in CLI patients. No limbs were lost
following interventions in claudicants (mean follow-up 16 months). In 24 patients with stent occlusion, 15 underwent
endovascular revision, only five (33%) ultimately remained patent (15.8 months after reintervention). In contrast, all nine
reinterventions for in-stent stenosis remained patent (17.8 months). Of 24 patients who underwent 37 endovascular
revisions for either occlusion or stenosis, eight (35%) had worsening of their runoff score (4.1 to 6.4). By Cox
proportional hazards analysis, hypertension (hazard ratio [HR] 0.35), TASC D lesions (HR 5.5), and runoff score > 5
(HR 2.6) significantly affected primary patency.
Conclusions: Self-expanding stents produce acceptable outcomes for treatment of SFA disease. Poorer patency rates are
associated with TASC D lesions and poor initial runoff score; HTN was associated with improved patency rates. Stent
occlusion and in-stent stenosis were not entirely benign; one-third of patients had deterioration of their tibial artery
runoff. Future studies of SFA interventions need to stratify TASC classification and runoff score. Further evaluation of
the long-term effects of SFA stenting on tibial runoff is needed. (J Vasc Surg 2008;47:967-74.)The role of endovascular treatment of femoropopliteal
artery occlusive disease continues to evolve. Early experi-
ences with stainless-steel stents showed no benefit over
angioplasty alone1-5 and stenting was relegated to salvage
procedure status in the face of failed angioplasty. More
recent randomized studies comparing superficial femoral
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doi:10.1016/j.jvs.2007.12.050artery (SFA) angioplasty alone with nitinol stenting have
shown a reduced incidence of restenosis with primary stent-
ing.6,7 Others have reported8 superior patency rates using
expanded polytetrafluoroethylene (ePTFE) covered stent
grafts (covered stents) compared with angioplasty alone.
In addition to angioplasty and stenting, technological
advances9-12 continue to create new treatment modali-
ties.
With the explosion in endovascular technology, a par-
adigm shift has occurred in vascular surgery. Reserving
open surgery for failures of endovascular therapy, many
centers are now using endovascular therapy as a first line
treatment13,14 for chronic lower extremity occlusive dis-
ease. A recent randomized trial comparing covered stents
with open femoral-popliteal artery bypass15 found no sig-
nificant difference in patency rates at 1 year. Another ran-
domized, prospective trial comparing preferential use of
endovascular therapy first, vs open surgery14 demonstrated
no significant difference in amputation-free survival at 6
months or in health-related quality of life at 1 year. How-
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cause mortality were found in the endovascular treatment
group after 2 years.
This latter finding raises concerns over the long-term
durability of endovascular therapy, and whether it compro-
mises the arterial runoff. A possible explanation for the
inferior long-term results of endovascular therapies in the
SFA could be a detrimental effect on the runoff arteries in
the lower extremity. A similar scenario was shown when
ePTFE grafts were compared with saphenous vein grafts for
femoral-popliteal artery bypass. Investigators16 found a
higher incidence of patients presenting with grade II acute
ischemia, and deterioration of arterial runoff when ePTFE
grafts thrombosed, compared with their vein counterparts.
Despite the encouraging results of endovascular therapy in
the short term, long-term data are lacking. To date, no
studies have evaluated the fate of runoff vessels after stent
thrombosis or in-stent restenosis. The purpose of this study
was to define outcomes of a large series of carefully followed
SFA stents, to determine risk factors, and mechanisms of
failure, and to determine whether bare metal nitinol stent
(bare stent) or covered stent placement adversely impairs
arterial runoff over time.
METHODS
We retrospectively reviewed the records of patients
who underwent stenting of chronic femoropopliteal artery
occlusive disease at University Medical Center and the
Southern Arizona Veterans Affairs Health Care System in
Tucson, Arizona between June 2003 and December 2006.
Institutional review board approval was obtained from both
institutions. Patients with prior stenting of the femoropop-
liteal arteries were excluded. Demographic features, co-
morbidities, indications for intervention, indications for
revision, and noninvasive vascular laboratory data were
recorded. Angiographic and anatomic data including lesion
length, lesion type (stenosis or occlusion), TransAtlantic
InterSociety Consensus (TASC I,18 TASC II19) classifica-
tion, and Society of Vascular Surgery (SVS) tibial runoff
score were tabulated by a single reviewer (DMI) to prevent
interobserver error. The SVS runoff score was calculated
from the completion angiogram, so any distal embolization
caused from the index endovascular procedure would be
included in the patient’s baseline runoff score. Results were
reported according to the recommended SVS reporting
standards.17
Intervention. All femoropopliteal endovascular pro-
cedures followed general guidelines, with some minor dif-
ferences that were operator dependent. The majority of
procedures were performed in an endovascular suite with
fixed imaging. The rest were completed in an operating
room with a portable C-arm. Nearly all procedures were
performed under local anesthesia and conscious sedation.
Contralateral femoral access was preferred, reserving ipsi-
lateral antegrade femoral access for patients found to have
focal, isolated distal SFA or popliteal artery occlusive dis-
ease. Intravenous heparin was routinely administered.Thrombolysis was used selectively if the interventionalist
was concerned about a large thrombus burden.
Lesions were generally crossed with 0.035 inch hydro-
philic wires. Lesions were preferentially treated with angio-
plasty and selective stenting. Balloon inflation times range
from 30 seconds to 2 minutes. Stents were reserved for
residual stenosis greater than 30% and flow-limiting dissec-
tions. Long segment disease and embolic lesions were
preferentially stented. The type of self-expanding nitinol
stent selected was determined by available inventory and
operator preference. Stents were routinely postdilated. If
more than one stent was required to treat a single lesion, a
minimum of 1 cm overlap was used.
Follow-up. Postprocedure, patients were adminis-
tered 150-300 mg of clopidogrel orally (if not previously
started), and maintained on 75 mg/day for at least 1
month. Patients also received aspirin indefinitely. Surveil-
lance included ankle-brachial index (ABI) and duplex ultra-
sound of the stented vessel within 30 days, and every 6-12
months thereafter in concert with clinical examinations.
For patients with noncompressible vessels, pulse volume
recordings, and toe pressures were routinely obtained. He-
modynamic failure was defined as inability to heal an isch-
emic ulcer, or an increase in ABI less than 0.15.
Secondary interventions. When patients presented
with stent occlusion, the decision to re-intervene depended
on the interventionalist taking care of the patient, the
patient’s symptoms, and patient preference. Some patients
refused to undergo either repeat endovascular procedures
or open bypass. As a general rule, an attempt to re-establish
stent patency was made if the patient had recurrence of
symptoms. Patients presenting with stent failure after two
to three endovascular procedures typically were recom-
mended to undergo open revascularization. For in-stent
restenosis, the threshold for intervention was a flow distur-
bance within the stented area associated with a decrease in
the ABI and a recurrence of symptoms. If a patient devel-
oped a flow disturbance in the region of the stent and it was
not associated with a decrease in the ABI, or recurrence of
symptoms, then the flow disturbance was observed. Most
of these patients presented with recurrent ischemic symp-
toms. The technique used to revise the in-stent restenosis
was determined by the operator. For stent occlusions,
thrombolysis was preferred. After thrombolysis, if a residual
stenosis was found at the proximal or distal end of the stent,
angioplasty with or without additional nitinol stents were
typically used. If a long residual in-stent restenosis was
present, either atherectomy or placement of a covered stent
was usually employed.
Statistical analysis. Data were entered into an Excel
spreadsheet (Microsoft, Redmond, Wash). Statistical anal-
ysis was performed using Stata, version 9.2 (Stata, College
Station, Tex). Kaplan-Meier survival product limit method
was applied to patency rates and limb salvage rate. The Cox
proportional hazard model was used to calculate covariates
of interest on patency and limb salvage rates. 2 test for
independence was used on dichotomous variables, and
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of P  0.05 considered statistically significant.
RESULTS
Demographics and indications. A total of 95 pa-
tients (80% male) underwent stenting of chronic femoro-
popliteal occlusive disease in 109 legs. The distribution of
comorbidities is delineated in Table I. Smoking was
defined as active smoking. Chronic renal insufficiency
was defined as serum creatinine 1.5 mg/dl. Hyperten-
sion was defined as requirement of 1 antihypertensive
medications. Diabetes mellitus includes both type I and
type II. Eight (8%) patients had end-stage renal failure.
Indications for intervention included claudication in 71
limbs (65%), ischemic rest pain in 12 limbs (11%), and
tissue loss in 26 limbs (24%). Thirty-one patients (28%)
underwent adjuvant inflow or outflow procedures, not all
were performed concurrently. Thrombolysis was used in
19% of cases. Three patients had undergone previous femoral-
popliteal artery bypass, and one patient had a prior an-
gioplasty of the SFA in an area separate from the stent
placement. The TASC classifications and runoff scores
are summarized in Table II. The frequencies of stent
types are listed in Table III.
Clinical results. The mean lesion treatment length
was 15.7 centimeters (cm) (range 2-43 cm, standard error
Table I. Demographic and clinical data
Characteristic Number
Male 76 (80%)
Diabetes mellitus 42 (44%)
Tobacco use (active) 34 (36%)
Hypertension 80 (84%)
Hyperlipidemia 72 (76%)
Coronary artery disease 45 (47%)
Chronic renal insufficiency 24 (25%)
Indication Number
Claudication 71 (65%)
Ischemic rest pain 12 (11%)
Tissue loss 26 (24%)
Table II. Angiographic anatomic data
Category TASC I (2000) TASC II (2007)
A 19 (17%) 31 (28%)
B 32 (30%) 49 (45%)
C 46 (42%) 17 (16%)
D 12 (11%) 12 (11%)
Runoff score Number
1-3 42 (39%)
3.5-5 15 (14%)
5.5-7 32 (29%)
7.5-10 20 (18%)
TASC, TransAtlantic InterSociety Consensus classification.18,19
Runoff score published by the Society of Vascular Surgery.171.06). An average of 1.9 stents (range 1-5) was used for eachlimb.The distribution of stent types is shown inTable IV.The
mean pre- and postintervention ABI were 0.59 and 0.89,
respectively (mean change 0.30). Fifty-five (50%) limbs
underwent intervention for native arterial occlusions; 11
(10%) were in the popliteal artery. Two of the 11 stents
placed in the popliteal artery crossed the knee joint; the
other nine popliteal stents were placed in the above-knee
segment. Mean runoff score was 4.6. A total of eight
patients (7%) ultimately required amputation (mean 3.1
months), only one underwent open bypass prior to ampu-
tation. All of the eight patients that required amputation
initially presented with critical limb ischemia. Seven pa-
tients (6%) underwent open bypass for stent failure. The
average follow-up was 16 months (range 0.25-44). A total
of 72 patients were available for follow-up at 1 year and
eight patients at 3 years. The primary, primary-assisted,
secondary patency and limb salvage rates were 63%, 70%,
78%, 75% at 1 year and 52%, 64%, 59%, 75% at 3 years (see
Table III. Stent data
Primary stent Number
Viabahn (W.L. Gore & Assoc., Inc.,
Flagstaff, Ariz)
19 (17%)
Luminex (C.R. Bard, Inc., Murray
Hill, NJ)
18 (16%)
Protégé (EV3, Plymouth, Minn) 16 (15%)
Symphony (Boston Scientific, Natick,
Mass)
15 (14%)
Zilver (Cook Medical Inc.,
Bloomington, Ind)
13 (12%)
Absolute (Abbott Laboratories,
Abbott Park, Ill)
6 (6%)
Xpert (Abbott) 5 (5%)
Smart (Cordis Corp., Miami Lakes,
Fla)
3 (3%)
Xceed (Abbott) 1 (1%)
Mixed (Absolute/Protégé) 1 (1%)
Nitinol (not specified) 12 (11%)
Total 109
Table IV. Cox proportional hazard evaluating covariates
against primary patency
Risk factor Hazard ratio P value
95% confidence
interval
Sex 0.81 .687 0.297 2.228
Diabetes 1.49 .271 0.732 3.044
Tobacco 1.25 .607 0.536 2.903
Hypertension 0.35 .028 0.135 0.892
Hyperlipidemia 1.81 .183 0.756 4.352
Renal insufficiency 0.87 .765 0.352 2.154
Heart disease 0.63 .211 0.309 1.296
Indication 1.60 .258 0.707 3.651
Runoff score 2.59 .024 1.133 5.932
TASC (2007) B 0.90 .831 0.359 2.277
TASC (2007) C 1.43 .536 0.460 4.444
TASC (2007) D 5.52 .009 1.534 19.845
TASC, TransAtlantic InterSociety Consensus classification.19Figs 1 and 2). By Cox proportional hazards analysis, hyper-
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5.5), and runoff score  5 (HR 2.6) significantly affected
primary patency (Table IV). Although gender did not
significantly affect primary patency, there was a trend for
women (37%) to develop stent thrombosis or clinically signif-
icant in-stent restenosis, compared with men (29%). Primary
patency rates for TASC A and B lesions vs C and D lesions
were calculated for both TASC I (200018) and TASC II
(200719), but were not significantly different (Figs 3 and 4).
Secondary interventions. A total 33 patients pre-
sented with either stent occlusion or stent restenosis.
Twenty-one of these patients initially underwent interven-
tion for claudication, four for ischemic rest pain, and eight
for tissue loss. Twenty-four patients developed stent occlu-
sion at a mean of 5.2 months after implantation; nine
patients developed in-stent restenosis at a mean of 9.9
months after implantation. No specific peak systolic veloc-
ity (PSV) threshold criteria were used to mandate repair of
in-stent restenosis. Only stents identified to have flow dis-
turbances associated with a decrease in the ABI and recur-
rence of symptoms underwent angiographic evaluation and
secondary interventions. Of the stents that underwent re-
pair of in-stent restenosis, the average PSV was 361 cm/sec
(range 220-467 cm/sec). Only one stent had a PSV less
than 300 cm/sec; this patient had a decrease in the ABI
from 0.9 to 0.68 and recurrence of claudication symptoms.
The average decrease in ABI for patients undergoing sec-
ondary intervention for in-stent restenosis was 0.43 (range
0.10-0.88).
Of 24 patients with stent occlusion, nine underwent
Fig 1. Patency data.
Fig 2. Limb salvage data (critical limb ischemia only).no further endovascular treatment (one bypass, two am-putations, six no intervention). The remaining 15 patients
with stent occlusion underwent endovascular revision; 10
re-occluded (4.1 months), one underwent amputation (2
months), two developed restenosis, and two required no
further revisions. Ultimately, only five of the 15 patients
who underwent endovascular revision for stent occlusion
were patent at last follow up (15.8 months after reinterven-
tion). All nine patients that developed in-stent restenosis
remained patent after reintervention; eight remained
patent with an average follow-up of 20months after a single
revision, and one required retreatment 6 months later. The
endovascular techniques used to treat in-stent restenosis
were as follows: 11 covered stents (30%), 8 atherectomies
(22%), 6 nitinol stents (16%), 5 angioplasties (13%), and 7
patients that underwent thrombolysis alone (19%). When
comparing patients that developed stent occlusion with
patients that developed in-stent restenosis, the two groups
were similar. Patients that developed stent occlusion had a
mean treatment length of 19.1 cm, an average runoff score of
1.8, and had claudication as the indication in 63% of patients.
Patients that developed in-stent restenosis had a mean treat-
ment length of 12.4 cm, a mean runoff score of 1.8, and had
claudication as the indication in 67% of patients.
We analyzed the patients’ presenting symptoms when
stent occlusion or restenosis was diagnosed. Eight of the 33
patients (24%) presenting with either stent occlusion or
restenosis, had grade II acute ischemia (pain with or with-
out neurologic impairment). The remaining 25 patients
Fig 3. Patency data stratified by TASC 1 (2000) classification.
TASC, TransAtlantic InterSociety Consensus classification.18
Fig 4. Patency data stratified by TASC II (2007) classification.
TASC, TransAtlantic InterSociety Consensus classification.19that presented with either stent occlusion or restenosis
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not acute grade II ischemia. None of the patients that
underwent secondary intervention were asymptomatic.
Among the eight patients that presented with acute grade
II ischemia, four initially underwent intervention for clau-
dication. Seven patients had stent occlusion, and one had a
long segment, high grade stenosis. Following reinterven-
tion, six (75%) presented a second time with recurrent stent
failure, three of whom presented again with grade II isch-
emic symptoms. Only two of the eight stents ultimately
remained patent at long-term follow up. Among the re-
maining 25 patients that presented with stent failure and
did not have grade II ischemia, 16 underwent endovascular
revision; only six (37%) presented a second time with stent
failure (two with acute grade II ischemia), and nine (56%)
ultimately remained patent at long-term follow up.
Comparing stent types, the mean lesion treatment
length was 25.4 cm in patients that had covered stents
placed at their initial intervention, and 13.7 cm in those
who had bare stents placed. Claudication was the indication
for the initial intervention in 17 (89%) of patients that had
covered stents placed, and tissue loss in two (11%). In
contrast, claudication was the indication in 54 (60%) pa-
tients that had bare stents placed, rest pain in 12 (13%), and
tissue loss in 24 (27%). The SVS runoff scores were 3.92
and 4.79 in patients with covered stents and bare stents,
respectively. In patients that presented with either initial
stent occlusion or restenosis, patients that had covered
stents were statistically more likely to present with acute
ischemic symptoms (Fisher exact, P  .047) than patients
with bare stents. The primary patency rates between cov-
ered stents and nitinol stents were not significantly different
(P  .48), but because of the small number of covered
stents, the standard error became greater than 10% after 2
months.
We also analyzed the arterial runoff in patients present-
ing with either stent occlusion or stenosis. Of the 24
patients who underwent endovascular revision for either
occlusion or restenosis, 22 had adequate visualization of
the tibial arteries to determine the runoff score. An addi-
tional patient with untreated stent occlusion underwent
angiography and had sufficient visualization of the tibial
arteries to determine the runoff score. Eight patients (35%)
had worsening of their runoff score from an average score
of 4.1 to 6.6 (P  .002). The deterioration in the runoff
score occurred an average 12 months (range 2-24 months)
after the initial runoff score had been calculated from the
completion angiogram. Among these eight patients, five
presented with occlusion, and three presented with steno-
sis. The average lesion treatment length was 17 centime-
ters. Only one of these eight patients had a covered stent.
We also reviewed the angiograms of the 24 patients that
underwent endovascular revision to see if stent fracture had
occurred. Only two stent fractures were identified, both
were Luminex stents. One was the stent that became in-
fected and required removal. It was placed in the above
knee popliteal artery, did not cross the knee joint, and was
removed 3 months after implantation. The other stent wasplaced in the distal superficial femoral artery and was asso-
ciated with stent occlusion 14 months later.
Complications. A total of 36 complications (Table V)
were identified in 30 patients (28%). The most common
complications were early (on table or 30 days) thrombo-
sis (9%), hemodynamic failure (6%), and perforation (5%).
Hemodynamic failure was defined as either as an increase in
ABI less than 0.15 (three patients), or a failure to heal
ischemic ulcers, which occurred in four (4%) patients with
tissue loss. All other patients improved their symptoms. All
five perforations were treated by endovascular methods
(three covered stents, two coils). Three patients (3%) died
(12, 18, and 18 days postprocedure). All three patients that
died within 30 days of stent implantation were treated for
tissue loss. These patients were ill prior to the procedure,
died at home, and did not sustain any other known com-
plication in the periprocedure period. Of the two infectious
complications, one patient developed an infected stent
requiring stent removal, and open bypass. The other devel-
oped a peri-stent abscess that was drained percutaneously
and resolved. This patient had bacterial endocarditis that
likely preceded stent placement. Both of the infectious
complications occurred in patients that had bare nitinol
stents.
DISCUSSION
The range of reported outcomes for endovascular treat-
ment of femoropopliteal artery occlusive disease fluctuates
widely. With the recent explosion of technological ad-
vances, numerous treatment options are available, and no
single algorithm is widely accepted. Since treatment pref-
erences vary by providers and region, comparisons with the
literature are difficult. Reported series may differ with re-
spect to whether angioplasty and selective stenting vs pri-
mary stenting is the preferred treatment, the average lesion
treatment length, and whether technical failures are in-
cluded in patency data. Other series have reported resteno-
sis6,7,28 rates instead of patency rates. Furthermore, some
reports mix iliac or tibial artery occlusive disease with
femoropopliteal disease, making comparisons even more
challenging. Clearly, lesion length has been demonstrated
to affect patency,18-20 with long lesions faring poorly com-
Table V. Complications (30 days)
Complication Number
Early thrombosis 10 (9%)
Hemodynamic failure 7 (6%)
Perforation 5 (5%)
Death 30 days 3 (3%)
Pseudoaneurysm 2 (2%)
Hematoma 2 (2%)
Distal embolization 2 (2%)
Deep venous thrombosis 2 (2%)
Infection 2 (2%)
Acute renal failure 1 (1%)pared with short focal ones. Similarly, nitinol stents have
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older stainless steel devices.
Despite the difficulties interpreting the literature, our
results are comparable with other similar series (see Table
VI). Some reports demonstrated primary patency rates of
70%-85% at 1 year with angioplasty22,24 or stenting.27
These series describe treatment for relatively short lesions.
Our series consisted of long (nearly 16 cm) segment dis-
ease, among the longest reported in the literature. Two
other reports25,26 of femoropopliteal stenting for long (16
cm) segment disease demonstrated similar results, 56%, and
54% 1 year patency vs 63% in our study.
The factor most strongly associated with stent failure
was a TASC D lesion. We calculated both the original
TASC I18 and the revised TASC II19 classification for all
treated lesions. Results after endovascular therapy for
TASCD lesions were significantly inferior when using both
the original TASC I (HR 5.2) as well as the revised TASC
II (HR  5.5) classifications. The revised TASC classifica-
tion essentially increased the numbers of A and B lesions,
and decreased the number of C lesions, but did not change
the D lesions. In our series, TASC B and TASC C lesions
were not statistically more likely to fail, compared with
TASC A lesions. This is possibly a type II statistical error
due to insufficient numbers. When TASC A and B were
compared against TASC C and D (Figs 3 and 4), the
patency rates showed a trend toward improved patency
with TASCA and B, but this was not statistically significant,
again most likely due to insufficient numbers.
In our series, poor arterial runoff was associated with a
higher risk of stent failure. This finding has been previously
Table VI. Comparative results of published series on endo
Series
Number
treated Average lesion len
Johnston 199222 (PTA only) 254 10 cm
Jamsen 200223 (PTA only) 218 5.2 cm
Clark 200424 (PTA only) 219 4 cm
Cheng 200325 (Stent only) 73 16 cm
Sabeti 200526 (Stent only) 65 16 cm (all greater tha
Lugmayr 200227 (Stent only) 54 3-4 cm 
Ihnat 109 15.7 cm
PTA, Percutaneous transluminal angioplasty; RR, relative risk; TASC, Tranreported in larger series22-24 for angioplasty, but not insmaller series with stenting.27 The association of poor
arterial runoff with stent failure makes intuitive sense, and
has also been shown for arterial bypass grafts.29,30 Others
have found diabetes24,26,27 and renal failure24 to be asso-
ciated with decreased patency, associations which we were
unable to confirm. Our series did show that patients with
hypertension had a decreased risk of stent failure. This
association has not been previously described. In our series,
84% of patients were taking at least one antihypertensive
medication. Perhaps this finding indicates overall improved
control of atherosclerotic risk factors.
One-third of the 23 patients with stent failure had
deterioration of their runoff vessels. We were not able to
identify any reports in the literature that evaluated the
incidence of progression of outflow disease after SFA stent-
ing. The SVS runoff score ranges from 1 through 10, with
10 being the worst (high resistance). In our series, the
reduction in runoff score is the equivalent of going from
two-vessel runoff to one-vessel runoff. While this may seem
clinically insignificant at first, this series does not have
long-term follow-up. If the reduction of runoff vessels
continues over time, it may raise concerns about the long-
term impact of endovascular stenting in the femoropopli-
teal arteries. Since the deterioration of runoff score oc-
curred over 12 months, it most likely was due to recurrent
thromboembolism from a long, stented segment instead of
atherosclerotic disease progression. We do not have angio-
graphic information for the patients that did not develop stent
occlusion or hemodynamically significant in-stent restenosis,
so we cannot know if this phenomenon is solely associated
with stent failure and revision or if it occurs in widely patent
ular therapy for femoropopliteal artery occlusive disease
Primary patency
Technical failures
included
Factors effecting
patency (RR)
70% 1 y 4% Runoff
57% 2 y
50% 3 y
43% 5 y
46% 1 y 16.5% Runoff
25% 5 y
87% 1 y 5% Runoff (8.5)
80% 2 y Diabetes (5.5)
69% 3 y Renal failure (4.0)
55% 5 y
56% 1 y 0% Indication
35% 2 y Lesion  10 cm
22% 4 y
m) 54% 1 y 0% Diabetes (3.8)
87% 1 y 0% Diabetes
85% 2 y
76% 3 y
63% 1 y 0% Runoff (2.6)
52% 2 y TASC D (5.5)
52% 3 y
tic InterSociety Consensus classification.19vasc
gth
n 5 c
sAtlanstents as well.
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presented with stent occlusion compared with in-stent
restenosis. Although these numbers are small, only one-
third of patients treated for stent occlusion maintained
stent patency by the end of the study period, compared
with 100% of patients treated for in-stent restenosis. This
raises the question of whether patients presenting with
stent occlusion could undergo secondary intervention prior
to occlusion and positively impact long-term patency, sim-
ilar to vein graft stenosis. Currently, our practice is to
perform ABI and duplex ultrasound on the day following
the endovascular procedure, at three months, and every 6
months thereafter. Despite general adherence to this pro-
tocol, some patients thrombose their stents in proximity to
a normal duplex ultrasound. In fact, seven (28%) of the
secondary procedures for stent occlusion in this series dem-
onstrated no detectable stenotic lesions once thrombolysis
was complete (six had previously been treated with covered
stents). Consequently, we believe some patients may
thrombose their stents with little or no warning while
others will gradually develop a stenotic lesion that can be
detected on surveillance duplex. More frequent follow-up
would be unlikely to yield benefit in the former group. In
our experience, the latter group frequently develops recur-
rent symptoms prior to stent occlusion. Elucidation of the
optimal frequency for follow-up will require further study.
Similarly, a trend was noted toward decreased patency
in patients who presented with acute grade II ischemia
from stent failure, compared with patients treated for re-
current symptoms from stent failure, and did not have acute
grade II limb ischemia. Despite the small numbers, only
25% of patients who presented with acute limb threat
maintained patency by the end of the study period, com-
pared with 56% of patients treated for recurrence of symp-
toms from stent failure, who did not have limb threat. We
are now more likely to perform open bypass on patients
who present with acute limb threat (acute grade II isch-
emia) after stent failure.
We found patients with covered stents were statistically
more likely than those with bare stents to present with
symptoms of acute (grade II) ischemia when presenting
with stent occlusion or restenosis. Similarly, ePTFE femoral-
popliteal artery bypass graft failure16 is associatedwith a higher
incidence of acute grade II ischemia. In our series, the groups
were not similarly matched. While the ePTFE covered
stent-graft group had a higher incidence of claudicants
(89% vs 60%), and a slightly better mean runoff score (3.9
vs 4.8), the lesion treatment length was nearly twice as long
as the bare metal nitinol stents (25.4 vs 13.7 cm). Interest-
ingly, in the ePTFE group, only one patient (5.3%) had
deterioration in the tibial runoff vessels, compared with
seven patients (7.7%) in the baremetal stent group. Perhaps
the association with acute grade II ischemia is more related
to loss of collaterals, and acute thrombosis of a long stented
segment, and not related to the ePTFE. Another possibility
is that the thrombus burden extends distally into the tibial
arteries, causing the grade II ischemia, but then reverts to
its baseline patency with prompt thrombolysis. With eightdifferent stent types in addition to the ePTFE covered stent
grafts, this series is not large enough to perform any addi-
tional subgroup analysis regarding the influence of stent
type.
Our practice has also shifted over time. We are now less
likely to pursue endovascular treatment techniques in pa-
tients with TASC D lesions, patients with poor tibial artery
runoff, and patients with extensive tissue loss. Further-
more, in patients considered to be very poor candidates for
open bypass, we are more likely to recommend primary
amputation instead of an endovascular attempt in those
with complex lesions (such as TASC D) or severe tissue
loss. Most of our patients that underwent amputation after
failed endovascular attempt would now undergo primary
amputation. Other investigators31 have reported similar
findings. We have also adopted a general policy of perform-
ing only two endovascular attempts to revascularize a leg.
After two endovascular therapeutic failures over a short
period of time we convert to open bypass.
The weaknesses of this study include its retrospective
nature, the lack of randomization, the lack of a clear protocol
for endovascular therapies, and the lack of a standardized
algorithm in choosing endovascular treatment as opposed to
open surgical revascularization. Since we retrospectively
searched our database for patients that had stents implanted
into the superficial femoral or popliteal arteries, data regarding
initial technical failures is lacking. Table III.
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